Oncolytics Biotech Inc. (NASDAQ:ONCY – Get Free Report) shares dropped 0.7% on Monday . The stock traded as low as $0.93 and last traded at $0.95. Approximately 78,988 shares changed hands during mid-day trading, a decline of 70% from the average daily volume of 266,283 shares. The stock had previously closed at $0.96.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Oncolytics Biotech in a report on Wednesday, August 21st.
View Our Latest Research Report on ONCY
Oncolytics Biotech Trading Down 0.7 %
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. During the same quarter last year, the business earned ($0.09) earnings per share. Analysts predict that Oncolytics Biotech Inc. will post -0.29 EPS for the current year.
Institutional Investors Weigh In On Oncolytics Biotech
An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech at the end of the most recent reporting period. Institutional investors own 6.82% of the company’s stock.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
- Five stocks we like better than Oncolytics Biotech
- Canadian Penny Stocks: Can They Make You Rich?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Overbought Stocks Explained: Should You Trade Them?
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- Airline Stocks – Top Airline Stocks to Buy Now
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.